ISRCTN45178534 https://doi.org/10.1186/ISRCTN45178534

Treatment of Fabry patients greater than 18 years with enzyme supplementation therapy: comparison of efficacy and toxicity of low dose (0.2 mg/kg) Fabrazyme® (agalsidase beta) or Replagal® (agalsidase alfa)

Submission date
20/12/2005

Registration date
20/12/2005

Last Edited
04/07/2019

Recruitment status
No longer recruiting

Overall study status
Completed

Condition category
Nutritional, Metabolic, Endocrine

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr A C Vedder

Contact details
Academic Medical Centre
Department of Internal Medicine, F4-247
PO Box 22660
Amsterdam
Netherlands
1105 AZ
+31 (0)20 566 4558
a.c.vedder@amc.uva.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
NTR216

Study information

Scientific Title
Treatment of Fabry patients greater than 18 years with enzyme supplementation therapy: comparison of efficacy and toxicity of low dose (0.2 mg/kg) Fabrazyme® (agalsidase beta) or Replagal® (agalsidase alfa)

Study objectives
Evaluation of efficacy and safety of two different formulas of alfa-Galactosidase A, agalsidase beta (Fabrazyme®) and agalsidase alpha (Replagal®) in an equal dose of 0.2 mg/kg in order to detect any differences between these two drugs.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Received from the local medical ethics committee

Study design
Multicentre, randomised, active controlled, factorial trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Fabry disease

Interventions
Patients will receive 0.2 mg/kg Fabrazyme® (agalsidase beta) or 0.2 mg/kg Replagal®(agalsidase alpha), every two weeks for a minumum of 12 months. If there is treatment failure (progression of renal disease, cardiac disease and/or a new cerebral stroke or TIA) during or after this period, patients will be advised to switch to Fabrazyme 1.0 mg/kg/2 weeks.

Intervention Type

Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Agalsidase beta (Fabrazyme®), agalsidase alpha (Replagal®)

Primary outcome measure
Wall-thickness (septum and left and right ventricle wall)/end-diastolic volume) on echocardiography.

Secondary outcome measures
1. Improvement of renal function as measured by GFR
2. Reduction of glycolipid accumulation in skin tissue (LM and biochemistry)
3. Reduction in pain as measured by the BPI
4. Reduction in glycosphingolipid in plasma and 24-hr urine
5. Quality of life scores (36-item Short Form Health Survey [SF-36])

Overall study start date
29/05/2001

Completion date
31/12/2005

Eligibility

Key inclusion criteria
1. The patient must have given written informed consent
2. Patients must be 18 years or older
3. Patient must have a current diagnosis of Fabry disease
4. Patients must have a decreased alpha-Gal activity or proven alfa-Gal A mutation
5. Female patients must have a negative pregnancy test, and must use a medically accepted method of contraception
6. Patients must be willing to comply to the evaluation program
7. Patients must have a clinical presentation consistent with either typical or atypical Fabry disease

Patients must have at least one major or two minor objective criteria:
Major:
1. Severe acroparesthesias, that cannot satisfactorily be controlled with Carbamazepine
2. Decreased glomerular filtration rate (GFR) less than 80 ml/min
3. Proteinuria greater than 300 mg/ml
4. Documented cerebrovascular accident (CVA)
5. Cardiac infarction
6. Hypertrophic non-obstructive cardiomyopathy resulting in decreased exercise tolerance
7. Rhythm disturbances necessitating a pacemaker
8. Multiple lacunar infarctions on magnetic resonance imaging (MRI)

Minor:
1. Documented transient ischaemic attack (TIA)

2. Cardiac hypertrophy on echo or MRI
3. Atrial fibrillation
4. Intraventricular conduction abnormality
5. Sensoric hearing loss as shown on a hearing test
6. Severe vertigo
7. Micro-albuminuria greater than 50 mg/L
8. Mild to moderate acroparesthesias
9. Gastro-intestinal complaints that can not be explained by other medical conditions than Fabry disease

Participant type(s)
Patient

Age group
Adult

Lower age limit
18 Years

Sex
Both

Target number of participants
At least 18 (9 in each group). 24 recruited as of Jan'06

Total final enrolment
34

Key exclusion criteria
1. Patient is pregnant or lactating
2. Patient is unwilling to comply to the evaluation program

Date of first enrolment
29/05/2001

Date of final enrolment
31/12/2005

Locations

Countries of recruitment
Netherlands

Study participating centre
Academic Medical Centre
Amsterdam
Netherlands
1105 AZ

Sponsor information

Organisation
Academic Medical Centre (AMC) (The Netherlands)

Sponsor details
Department of Internal Medicine
Meibergdreef 9
Amsterdam
Netherlands
1105 AZ

Sponsor type
Hospital/treatment centre

Website
http://www.amc.uva.nl

ROR
https://ror.org/03t4gr691

Funder(s)

Funder type
Government

Funder Name
The Dutch Health Care Insurance Board (CVZ) (The Netherlands)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	11/07/2007	04/07/2019	Yes	No